MediciNova Inc - Company Profile
Powered by 
All the data and insights you need on MediciNova Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date MediciNova Inc Strategy Report
- Understand MediciNova Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MediciNova Inc (MediciNova) is a biopharmaceutical company that focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurological, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and respiratory diseases. The company’s non-core programs formulations developed for indications include treatment of bronchial asthma; interstitial cystitis; solid tumors; and for the treatment of preterm labor. It has partnerships with various companies such as Angiogene Pharmaceuticals Ltd, Kyorin Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd and Meiji Seika Kaisha Ltd, to develop and commercialize its products. The company is headquartered in La Jolla, California, the US.
Headquarters
United States of America
Address
Suite 650, 4275 Executive Square, La Jolla, California, 92037
Website
medicinova.com
Telephone
1 858 3731500
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MNOV (NASD)
Revenue (2022)
$1.0M
EPS
XYZ
Net Income (2022)
XYZ
39.1%
(2022 vs 2021)
Market Cap*
$77.0M
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
MediciNova Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Product: |
| Pipeline: |
| Core programs:- |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company extended its contract with Biomedical Advanced Research and Development Authority (BARDA) to develop MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury. |
| 2022 | Contracts/Agreements | In August, the company entered into collaboration with the University Health Network, for the evaluation of MN-166 (ibudilast) in the treatment of Long COVID. |
| 2022 | Contracts/Agreements | In June, the company announced a research collboration with Juntendo University, School of Medicine to develop MN-001 (tipelukast) for the treatment of lipid metabolism and metabolic syndrome. |
Competitor Comparison
| Key Parameters | MediciNova Inc | Amgen Inc | Biogen Inc | Intercept Pharmaceuticals Inc | BioDelivery Sciences International Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | La Jolla | Thousand Oaks | Cambridge | Morristown | Raleigh |
| State/Province | California | California | Massachusetts | New Jersey | North Carolina |
| No. of Employees | 13 | 26,700 | 7,570 | 341 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeff Himawan Ph.D. | Chairman | Executive Board | - | 58 |
| Yuichi Iwaki, M.D., Ph.D. | Chief Executive Officer; Founder; President; Director | Executive Board | 2006 | 73 |
| Kazuko Matsuda, M.D., Ph.D. | Director; Chief Medical Officer | Executive Board | 2011 | 57 |
| Jason J. Kruger | Chief Financial Officer | Senior Management | 2022 | 46 |
| David H. Crean | Chief Business Officer | Senior Management | 2021 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward